1932

Abstract

Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-psych-020124-023532
2025-01-17
2025-02-09
Loading full text...

Full text loading...

/deliver/fulltext/psych/76/1/annurev-psych-020124-023532.html?itemId=/content/journals/10.1146/annurev-psych-020124-023532&mimeType=html&fmt=ahah

Literature Cited

  1. Abbar M, Demattei C, El-Hage W, Llorca PM, Samalin L, et al. 2022.. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. . BMJ 376::e067194
    [Crossref] [Google Scholar]
  2. Abdallah CG, Roache JD, Gueorguieva R, Averill LA, Young-McCaughan S, et al. 2022.. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. . Neuropsychopharmacology 47:(8):157481
    [Crossref] [Google Scholar]
  3. Adams B. 2023.. MAPS applies for FDA approval of MDMA-assisted therapy for PTSD. . Forbes, Dec. 13. https://www.forbes.com/sites/benjaminadams/2023/12/15/maps-applies-for-fda-approval-of-mdma-assisted-therapy-for-ptsd/?sh=1a506c0a29da
    [Google Scholar]
  4. Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. 2022.. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. . Psychopharmacology 239:(6):19892010
    [Crossref] [Google Scholar]
  5. Aghajanian GK, Foote WE, Sheard MH. 1968.. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. . Science 161:(3842):7068
    [Crossref] [Google Scholar]
  6. Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, et al. 2023.. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. . N. Engl. J. Med. 388:(25):231525
    [Crossref] [Google Scholar]
  7. Badiani A, Oates MM, Robinson TE. 2000.. Modulation of morphine sensitization in the rat by contextual stimuli. . Psychopharmacology 151::27382
    [Crossref] [Google Scholar]
  8. Bai N. 2023.. Ketamine's effect on depression may hinge on hope. . Stanford Medicine, Oct. 19. https://med.stanford.edu/news/all-news/2023/10/ketamine.html
    [Google Scholar]
  9. Barber PW. 2018.. Psychedelic Revolutionaries: Three Medical Pioneers, the Fall of Hallucinogenic Research and the Rise of Big Pharma. New York:: Bloomsbury
    [Google Scholar]
  10. Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. 2018.. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. . Cereb. Cortex 28:(11):393950
    [Crossref] [Google Scholar]
  11. Beets MW, Weaver RG, Ioannidis JP, Pfledderer CD, Jones A, et al. 2023.. Influence of pilot and small trials in meta-analyses of behavioral interventions: a meta-epidemiological study. . Syst. Rev. 12:(1):21
    [Crossref] [Google Scholar]
  12. Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, et al. 2022.. Percentage of heavy drinking days following psilocybin-assisted psychotherapy versus placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. . JAMA Psychiatry 79:(10):95362
    [Crossref] [Google Scholar]
  13. Borgogna NC, Owen T, Vaughn J, Johnson DAL, Aita SL, Hill BD. 2024.. So how special is special K? A systematic review and meta-analydid of ketamine for PTSD RCTs. . Eur. J. Psychotraumatol. 15::2299124
    [Crossref] [Google Scholar]
  14. Burke MJ, Blumberger DM. 2021.. Caution at psychiatry's psychedelic frontier. . Nat. Med. 27::168788
    [Crossref] [Google Scholar]
  15. Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, et al. 2023.. Beyond the 5-HT2A receptor: classic and nonclassic targets in psychedelic drug action. . J. Neurosci. 43::747282
    [Crossref] [Google Scholar]
  16. Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, et al. 2018.. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. . Am. J. Psychiatry 175:(7):62030
    [Crossref] [Google Scholar]
  17. Cao D, Yu J, Wang H, Luo Z, Liu X, et al. 2022.. Structure-based discovery of nonhallucinogenic psychedelic analogs. . Science 375::40311
    [Crossref] [Google Scholar]
  18. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, et al. 2021.. Trial of psilocybin versus escitalopram for depression. . N. Engl. J. Med. 384:(15):140211
    [Crossref] [Google Scholar]
  19. Chen X, Hou X, Bai D, Lane R, Zhang C, et al. 2023.. Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA. . Neuropsychiatr. Dis. Treat. 19::693707
    [Crossref] [Google Scholar]
  20. Cunliffe R. 2023.. David Nutt: “It's the biggest breakthrough in mental health in 50 years. .” New Statesman, July 19. https://www.newstatesman.com/encounter/2023/07/david-nutt-interview-depression-treatment-mental-health
    [Google Scholar]
  21. Dakwar E, Levin F, Hart CL, Basarba C, Choi J, et al. 2019.. A single ketamine infusion combined with notivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. . Am. J. Psychiatry 177::12533
    [Crossref] [Google Scholar]
  22. Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, et al. 2020.. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. . Am. J. Psychiatry 176::92330
    [Crossref] [Google Scholar]
  23. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, et al. 2018.. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. . JAMA Psychiatry 75::13948
    [Crossref] [Google Scholar]
  24. Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, et al. 2019.. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. . JAMA Psychiatry 76::893903
    [Crossref] [Google Scholar]
  25. Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, et al. 2022.. Increased global integration in the brain after psilocybin therapy for depression. . Nat. Med. 28:(4):84451
    [Crossref] [Google Scholar]
  26. de Almeida RN, Galvão ACDM, Da Silva FS, Dos Santos Silva EA, Palhano-Fontes F, et al. 2019.. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. . Front. Psychol. 10::1234
    [Crossref] [Google Scholar]
  27. Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, et al. 2021.. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. . Transl. Psychiatry 11::574
    [Crossref] [Google Scholar]
  28. Dyck E. 2006.. Hitting highs at rock bottom: LSD treatment for alcoholism, 1950–1970. . Soc. Hist. Med. 19:(2):31329
    [Crossref] [Google Scholar]
  29. Dyck E. 2008.. Psychedelic Psychiatry: LSD from Clinic to Campus. Baltimore, MD:: Johns Hopkins Univ. Press
    [Google Scholar]
  30. Ezquerra-Romano II, Lawn W, Krupitsky E, Morgan CJA. 2018.. Ketamine for the treatment of addiction: evidence and potential mechanisms. . Neuropharmacology 142::7282
    [Crossref] [Google Scholar]
  31. FDA (Food Drug Adm.). 2022.. FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. . US Food & Drug Administration, Febr. 16. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray
    [Google Scholar]
  32. FDA (Food Drug Adm.). 2023.. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. . US Food & Drug Administration, Oct. 10. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
    [Google Scholar]
  33. Finney JW. 2000.. Limitations in using existing alcohol treatment trials to develop practice guidelines. . Addiction 95:(10):1491500
    [Crossref] [Google Scholar]
  34. Flameling LJ, Aday JS, van Elk M. 2023.. Expectancy effects cannot be neglected in MDMA-assisted therapy research. . ACS Chem. Neurosci. 14:(23):406263
    [Crossref] [Google Scholar]
  35. Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, et al. 2022.. Single-dose psilocybin for a treatment-resistant episode of major depression. . N. Engl. J. Med. 387:(18):163748
    [Crossref] [Google Scholar]
  36. Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, et al. 2022.. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. . Am. J. Psychiatry 179:(2):15262
    [Crossref] [Google Scholar]
  37. Graham M, Stepjanovic D, Chiu V, Hall W. 2023.. A provisional evaluation of Australia's medical cannabis program. . Int. J. Drug Policy 122::104210
    [Crossref] [Google Scholar]
  38. Griffiths RR. 2023.. Psychedelics: spirituality, mindfulness, and mortality–personal reflections and visions for the future. Paper presented at the Psychedelic Science 2023 meeting, Denver, CO:. https://psychedelicscience2023.sched.com/event/1NZEz/psychedelics-spirituality-mindfulness-and-mortality-personal-reflections-and-visions-for-the-future
    [Google Scholar]
  39. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, et al. 2016.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. . J. Psychopharmacol. 30:(12):118197
    [Crossref] [Google Scholar]
  40. Grinspoon L. 1981.. LSD reconsidered: Should clinical research be resumed?. Sciences 21:(1):2023
    [Crossref] [Google Scholar]
  41. Gross N. 2013.. Why Are Professors Liberal and Why Do Conservatives Care? Cambridge, MA:: Harvard Univ. Press
    [Google Scholar]
  42. Gumpper RH, Roth BL. 2024.. Psychedelics: Preclinical insights provide directions for future research. . Neuropsychopharmacology 49::11927
    [Crossref] [Google Scholar]
  43. Hall WD, Humphreys K. 2022.. Is good science leading the way in the therapeutic use of psychedelic drugs?. Psychol. Med. 52:(14):284951
    [Crossref] [Google Scholar]
  44. Hall WD, Lynskey M. 2020.. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. . World Psychiatry 19:(2):17986
    [Crossref] [Google Scholar]
  45. Humphreys K. 2023.. Clinical research: The samples are narrow, but at least the conclusions are broad. . J. Gen. Intern. Med. 38::281920
    [Crossref] [Google Scholar]
  46. Humphreys K, Piot P. 2012.. Scientific evidence alone is not sufficient basis for health policy. . BMJ 344::e1316
    [Crossref] [Google Scholar]
  47. Humphreys K, Saitz R. 2019.. Should physicians recommend replacing opioids with cannabis?. JAMA 321:(7):63940
    [Crossref] [Google Scholar]
  48. Humphreys K, Shover CL. 2020.. Recreational cannabis legalization presents an opportunity to reduce the harms of the U.S. medical cannabis industry. . World Psychiatry 19::19192
    [Crossref] [Google Scholar]
  49. Humphreys K, Shover CL, Andrews CM, Bohnert AS, Brandeau ML, et al. 2022.. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. . Lancet 399:(10324):555604
    [Crossref] [Google Scholar]
  50. Ionescu DF, Swee MB, Pavone KJ, Taylor N, Akeju O, et al. 2016.. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. . J. Clin. Psychiatry 77:(6):10114
    [Crossref] [Google Scholar]
  51. Jaster AM, González-Maeso J. 2023.. Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. . Mol. Psychiatry 28::3595612
    [Crossref] [Google Scholar]
  52. Johnson MW, Richards WA, Griffiths RR. 2008.. Human hallucinogen research: guidelines for safety. . J. Psychopharmacol. 22:(6):60320
    [Crossref] [Google Scholar]
  53. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. 2009.. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. . PNAS 106:(46):1957580
    [Crossref] [Google Scholar]
  54. Kahneman D, Tversky A. 1984.. Choices, values, and frames. . Am. Psychol. 39::34150
    [Crossref] [Google Scholar]
  55. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, et al. 2022.. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. . Nature 610::58291
    [Crossref] [Google Scholar]
  56. Kisely S, Connor M, Somogyi AA, Siskind D. 2023.. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. . Aust. N.Z. J. Psychiatry 57:(3):36278
    [Crossref] [Google Scholar]
  57. Krebs TS, Johansen PØ. 2012.. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. . J. Psychopharmacol. 26:(7):9941002
    [Crossref] [Google Scholar]
  58. Krebs TS, Johansen PØ. 2013.. Psychedelics and mental health: a population study. . PLOS ONE 8:(8):e63972
    [Crossref] [Google Scholar]
  59. Krizan Z, Windschitl PD. 2009.. Wishful thinking about the future: Does desire impact optimism?. Soc. Personal. Psychol. Compass 3:(3):22743
    [Crossref] [Google Scholar]
  60. Lee BH, Kim H, Park SH, Kim YK. 2007.. Decreased plasma BDNF level in depressive patients. . J. Affect. Disord. 101:(1–3):23944
    [Crossref] [Google Scholar]
  61. Lii TR, Smith AE, Flohr JR, Okada RL, Nyongesa CA, et al. 2023.. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. . Nat. Mental Health 1::87686
    [Crossref] [Google Scholar]
  62. Loo C, Glozier N, Barton D, Baune BT, Mills NT, et al. 2023.. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. . Br. J. Psychiatry 223::53341
    [Crossref] [Google Scholar]
  63. Ludwig A, Levine J, Stark L, Lazar R. 1969.. A clinical study of LSD treatment in alcoholism. . Am. J. Psychiatry 126:(1):5969
    [Crossref] [Google Scholar]
  64. Ludwig AM, Levine J, Stark LH. 1970.. LSD and Alcholism: A Clinical Study of Treatment Efficacy. Springfield, IL:: Charles T. Thomas
    [Google Scholar]
  65. MacCoun RJ. 1998.. Biases in the interpretation and use of research results. . Annu. Rev. Psychol. 49::25987
    [Crossref] [Google Scholar]
  66. MacCoun RJ, Paletz S. 2009.. Citizens’ perceptions of ideological bias in research on public policy controversies. . Political Psychol. 30:(1):4365
    [Crossref] [Google Scholar]
  67. Mangini M. 1998.. Treatment of alcoholism using psychedelic drugs: a review of the program of research. . J. Psychoactive Drugs 30:(4):381418
    [Crossref] [Google Scholar]
  68. McClure-Begley TD, Roth BL. 2022.. The promises and perils of psychedelic pharmacology for psychiatry. . Nat. Rev. Drug Discov. 21:(6):46373
    [Crossref] [Google Scholar]
  69. Mind Med. Aust. 2024.. Certificate in psychedelic-assisted therapies (CPAT). . Mind Medicine Australia. https://cpat.mindmedicineaustralia.org.au (accessed March 24, 2024 )
    [Google Scholar]
  70. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, et al. 2021.. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. . Nat. Med. 27::102533
    [Crossref] [Google Scholar]
  71. Mitchell JM, Ot'alora MG, van der Kolk B, Shannon S, Bogenschutz M, et al. 2023.. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. . Nat. Med. 29::247380
    [Crossref] [Google Scholar]
  72. Mithoefer MC, Grob CS, Brewerton TD. 2016.. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. . Lancet Psychiatry 3:(5):48188
    [Crossref] [Google Scholar]
  73. Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, et al. 2019.. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. . Science 364:(6436):eaat8078
    [Crossref] [Google Scholar]
  74. Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, et al. 2023.. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. . Nat. Neurosci. 26:(6):103241
    [Crossref] [Google Scholar]
  75. Montgomery SA, Åsberg M. 1979.. A new depression scale designed to be sensitive to change. . Br. J. Psychiatry 134:(4):38289
    [Crossref] [Google Scholar]
  76. Mustafa RA, McQueen B, Nikitin D, Nhan E, Zemplenyi A, et al. 2024.. 3,4-Methylenedioxymethamphetamine assisted psychotherapy for post-traumatic stress disorder: effectiveness and value. Evid. Rep. , Inst. Clin. Econ. Rev., Boston, MA:. https://icer.org/wp-content/uploads/2023/11/PTSD_Revised-Report_For-Publication_05142024.pdf
    [Google Scholar]
  77. Nayak SM, Bradley MK, Kleykamp BA, Strain EC, Dworkin RH, Johnson MW. 2023.. Control conditions in randomized trials of psychedelics: an ACTTION systematic review. . J. Clin. Psychiatry 84:(3):22r14518
    [Crossref] [Google Scholar]
  78. Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C, et al. 2023.. Ketamine for the treatment of major depression: a systematic review and meta-analysis. . EClinicalMedicine 62::102127
    [Crossref] [Google Scholar]
  79. Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, et al. 2020.. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3. . Am. J. Geriatr. Psychiatry 28:(2):12141
    [Crossref] [Google Scholar]
  80. Olson DE. 2020.. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. . ACS Pharmacol. Transl. Sci. 4:(2):56367
    [Crossref] [Google Scholar]
  81. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, et al. 2019.. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. . Psychol. Med. 49:(4):65563
    [Crossref] [Google Scholar]
  82. Perlmutter S, Campbell J, MacCoun R. 2024.. Third Millenium Thinking: Creating Sense in a World of Nonsense. New York:: Little, Brown Spark
    [Google Scholar]
  83. Petty RE, Cacioppo JT. 1984.. The effects of involvement on responses to argument quantity and quality: central and peripheral routes to persuasion. . J. Personal. Soc. Psychol. 46:(1):6981
    [Crossref] [Google Scholar]
  84. Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. 2016.. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. . Eur. Neuropsychopharmacol. 26:(4):75666
    [Crossref] [Google Scholar]
  85. Pollan M. 2019.. How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. New York:: Penguin
    [Google Scholar]
  86. Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, et al. 2019.. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. . Am. J. Psychiatry 176:(6):42838
    [Crossref] [Google Scholar]
  87. Psychedelic Frontier. 2013.. Ask Me Anything” Reddit Interview with Rick Doblin & MAPS. Psychedelic Frontier, Dec. 4. https://psychedelicfrontier.com/ask-me-anything-reddit-interview-rick-doblin-maps/
    [Google Scholar]
  88. Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, et al. 2023.. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. . JAMA 330:(9):84353
    [Crossref] [Google Scholar]
  89. Ray TS. 2010.. Psychedelics and the human receptorome. . PLOS ONE 5:(2):e9019
    [Crossref] [Google Scholar]
  90. Reif A, Bitter I, Buyze J, Cebulla K, Frey R, et al. 2023.. Esketamine nasal spray versus quetiapine for treatment-resistant depression. . N. Engl. J. Med. 389:(14):1298309
    [Crossref] [Google Scholar]
  91. Rettig RA, Jacobson PD, Farquhar CM, Aubry WM. 2007.. False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford, UK:: Oxford Univ. Press
    [Google Scholar]
  92. Sard H, Kumaran G, Morency C, Roth BL, Toth BA, et al. 2005.. SAR of psilocybin analogs: discovery of a selective 5-HT2C agonist. . Bioorg. Med. Chem. Lett. 15:(20):455559
    [Crossref] [Google Scholar]
  93. Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, et al. 2021.. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. . Neuron 109:(16):253544
    [Crossref] [Google Scholar]
  94. Shover CL, Davis CS, Gordon SC, Humphreys K. 2019.. Association between medical cannabis laws and opioid overdose mortality has reversed over time. . PNAS 116:(26):1262426
    [Crossref] [Google Scholar]
  95. Shover CL, Humphreys K. 2019.. Six policy lessons relevant to cannabis legalization. . Am. J. Drug Alcohol Abuse 45:(6):698706
    [Crossref] [Google Scholar]
  96. Sumner P, Vivian-Griffiths S, Boivin J, Williams A, Venetis CA, et al. 2014.. The association between exaggeration in health related science news and academic press releases: retrospective observational study. . BMJ 349::g7015
    [Crossref] [Google Scholar]
  97. Takahashi N, Yamada A, Shiraishi A, Shimuzu H, Goto R, Tominaga Y. 2021.. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. . BMC Psychiatry 21::526
    [Crossref] [Google Scholar]
  98. van Elk M, Fried EI. 2023.. History repeating: guidelines to address common problems in psychedelic science. . Ther. Adv. Psychopharmacol. 13:. https://doi.org/10.1177/20451253231198466
    [Crossref] [Google Scholar]
  99. von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, et al. 2023.. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. . EClinicalMedicine 56::101809
    [Crossref] [Google Scholar]
  100. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, et al. 2018.. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. . Psychol. Assess. 30:(3):38395
    [Crossref] [Google Scholar]
  101. Yaden DB, Griffiths RR. 2020.. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. . ACS Pharmacol. Transl. Sci. 4:(2):56872
    [Crossref] [Google Scholar]
  102. Yaden DB, Potash JB, Griffiths RR. 2022.. Preparing for the bursting of the psychedelic hype bubble. . JAMA Psychiatry 79:(10):94344
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-psych-020124-023532
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error